CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Botulinum Toxin A for Chronic Migraines: Clinical Effectiveness

Last updated: January 3, 2018
Project Number: RB1176-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness of botulinum toxin A for patients with chronic migraines?
  2. What is the clinical effectiveness of botulinum toxin A plus opioid derivatives for patients with chronic migraines?

Key Message

Two systematic reviews, six randomized controlled trials, and two non-randomized studies were identified regarding the clinical effectiveness of botulinum toxin A for patients with chronic migraines.